COMMUNIQUÉS West-GlobeNewswire
-
Eupraxia Pharmaceuticals Reaches its Enrollment Target for the RESOLVE Trial Investigating EP-104GI for the Treatment of Eosinophilic Esophagitis
15/10/2026 -
Jyong Biotech Announces Proposed Texas Facility to Support Potential Commercialization of Its Drug Candidates
15/10/2026 -
Nautilus Biotechnology to Announce Third Quarter 2026 Financial Results on October 27, 2026
15/10/2026 -
Recursion Announces $200 Million Oversubscribed Follow-On Offering, Clinical Data Updates, and Partnership Milestone
15/10/2026 -
NRx Pharmaceuticals Announces Receipt of FDA Labeling Review Letter for Preservative-Free Ketamine
15/10/2026 -
TOMI Environmental Solutions Reports Independent Lab Results Showing SteraMist iHP Is Effective Against Listeria Biofilm, a Leading Cause of Food Recalls
15/10/2026 -
CytoDyn to Host Investor Webcast
15/10/2026 -
PolyPid to Host Virtual Investor Day on Wednesday, October 28, 2026
15/10/2026 -
Sienna Announces October Dividend
15/10/2026 -
OneMedNet Adds Leading Hospital System Provider Network, Expanding By Up to 12 Hospitals
15/10/2026 -
Vivos Therapeutics Agrees to Acquire Minority Stake in SOD Sciences and 50% Interest in Proprietary Pseudohypoxia Test
15/10/2026 -
Novonesis Opens Doors to Students to Inspire the Next Generation of U.S. Biomanufacturing Talent
15/10/2026 -
UAE Banking Heavyweight Joins NeOnc as Global Brain-Cancer Drug Development Advances
15/10/2026 -
Quantum-Si Regains Compliance with Nasdaq Minimum Bid Price Requirement
15/10/2026 -
Alignment Health Expands Medicare Advantage Coverage to San Antonio for 2027
15/10/2026 -
DaltonTx awarded grant to accelerate AI-powered tuberculosis drug discovery
15/10/2026 -
iOnctura appoints Paul Sekhri as Chair of its Board of Directors
15/10/2026 -
Mission Therapeutics doses first Parkinson’s patient in Phase 1b study of potential disease-modifying treatment MTX325
15/10/2026 -
EXIT-CVD research consortium launches clinical studies to transform cardiovascular care across Europe
15/10/2026
Pages